According to SNS Insider data, the global market value of artificial intelligence in pharmaceuticals was $1.73 billion in 2024. By 2032, it is expected to grow to $13.46 billion. This represents an annual growth rate (CAGR) of 29.33% from 2025 to 2032.
It’s worth taking a look at the budgets right away. The traditional method of developing drugs can cost an average of 2.6 billion dollars. AI reduces this cost to about 1.5 billion dollars. According to a study by Boston Consulting Group, 75 molecules discovered by AI had entered clinical trials by 2023, with 67 remaining in active tests. Today, these numbers are certainly much larger. Interestingly, oncology alone accounts for about 50% of the share in molecules discovered in the early phases of research.